{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:44:19Z","timestamp":1790376259237,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"DOI":"10.7759\/cureus.87029","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:53:03Z","timestamp":1751291583000},"source":"Crossref","is-referenced-by-count":2,"title":["Euglycemic Diabetic Ketoacidosis Triggered by Sepsis in a Patient on Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor Therapy: A Case of Diagnostic and Therapeutic Challenges"],"prefix":"10.7759","author":[{"given":"Archana","family":"Ramalingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayele","family":"Tewadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"De Souza Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anitha","family":"Yelangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Elghul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow E","year":"2023","unstructured":"Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023, 11:10.1136\/bmjdrc-2023-003666","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12029","article-title":"A case of euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus and COVID-19","volume":"12","author":"Morrison N","year":"2020","unstructured":"Morrison N, Barnett K, Tantum J, Morrison HK, Whalen M. A case of euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus and COVID-19. Cureus. 2020, 12:e12029. 10.7759\/cureus.12029","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158481","article-title":"COVID-19-associated sepsis: potential role of phytochemicals as functional foods and nutraceuticals","volume":"25","author":"de Souza Goncalves B","year":"2024","unstructured":"de Souza Goncalves B, Sangani D, Nayyar A, et al.. COVID-19-associated sepsis: potential role of phytochemicals as functional foods and nutraceuticals. Int J Mol Sci. 2024, 25:10.3390\/ijms25158481","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-025-01074-z","article-title":"Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article","volume":"31","author":"Mehdi SF","year":"2025","unstructured":"Mehdi SF, Qureshi MH, Pervaiz S, et al.. Endocrine and metabolic alterations in response to systemic inflammation and sepsis: a review article. Mol Med. 2025, 31:16. 10.1186\/s10020-025-01074-z","journal-title":"Mol Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccc.2017.08.006","article-title":"Endocrine and metabolic alterations in sepsis and implications for treatment","volume":"34","author":"Ingels C","year":"2018","unstructured":"Ingels C, Gunst J, Van den Berghe G. Endocrine and metabolic alterations in sepsis and implications for treatment. Crit Care Clin. 2018, 34:81-96. 10.1016\/j.ccc.2017.08.006","journal-title":"Crit Care Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46243","article-title":"Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: expanding horizons beyond diabetes management","volume":"15","author":"Fatima A","year":"2023","unstructured":"Fatima A, Rasool S, Devi S, et al.. Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: expanding horizons beyond diabetes management. Cureus. 2023, 15:e46243. 10.7759\/cureus.46243","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters AL","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015, 38:1687-93. 10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5057","article-title":"Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy","volume":"9","author":"Bobrowski D","year":"2021","unstructured":"Bobrowski D, Kumar R, Wu PE, Lapointe-Shaw L. Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy. Clin Case Rep. 2021, 9:e05057. 10.1002\/ccr3.5057","journal-title":"Clin Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor SI","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015, 100:2849-52. 10.1210\/jc.2015-1884","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-9032","article-title":"Hyperglycemic crises in adult patients with diabetes","volume":"32","author":"Kitabchi AE","year":"2009","unstructured":"Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009, 32:1335-43. 10.2337\/dc09-9032","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v9.i12.226","article-title":"Guidelines and controversies in the management of diabetic ketoacidosis - a mini-review","volume":"9","author":"Islam T","year":"2018","unstructured":"Islam T, Sherani K, Surani S, Vakil A. Guidelines and controversies in the management of diabetic ketoacidosis - a mini-review. World J Diabetes. 2018, 9:226-9. 10.4239\/wjd.v9.i12.226","journal-title":"World J Diabetes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski L","year":"2019","unstructured":"Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019, 63:9-14. 10.1016\/j.ejim.2019.03.014","journal-title":"Eur J Intern Med"},{"key":"ref13","article-title":"Euglycemic diabetic ketoacidosis","author":"Plewa MC","year":"2025","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic diabetic ketoacidosis. StatPearls. StatPearls Publishing, Treasure Island; 2025."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1764532","article-title":"Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment","volume":"19","author":"Sampani E","year":"2020","unstructured":"Sampani E, Sarafidis P, Papagianni A. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. Expert Opin Drug Saf. 2020, 19:673-82. 10.1080\/14740338.2020.1764532","journal-title":"Expert Opin Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/372142-euglycemic-diabetic-ketoacidosis-triggered-by-sepsis-in-a-patient-on-sodium-glucose-co-transporter-2-sglt2-inhibitor-therapy-a-case-of-diagnostic-and-therapeutic-challenges","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T13:53:04Z","timestamp":1751291584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/372142-euglycemic-diabetic-ketoacidosis-triggered-by-sepsis-in-a-patient-on-sodium-glucose-co-transporter-2-sglt2-inhibitor-therapy-a-case-of-diagnostic-and-therapeutic-challenges"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.87029","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}